Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Antiautoimmune Drug Treatment Combined with Bone Marrow Transplant Cures Mouse Model of Type I Diabetes

By BiotechDaily International staff writers
Posted on 12 Jun 2013
Treatment with a drug to block autoimmune attack combined with transplantation of adult bone marrow cells or purified bone marrow progenitor cells restored the population of insulin-producing pancreatic beta cells and cured a mouse model of type I diabetes.

Investigators at the University of Missouri (Columbia, USA) had previously shown that a peptide drug (Ig-GAD2 ) comprising a 14 amino acid sequence isolated from the enzyme glutamic acid decarboxylase, induced immune modulation in hyperglycemic mice that was able to control pancreatic inflammation, stimulate beta-cell regeneration, and prevent type I diabetes progression. However, this treatment was unable to reverse the course of the disease despite eradication of inflammatory immune cells from the pancreas.

In a paper published in the May 28, 2013, online edition of the journal Diabetes the investigators reported that the reason for this failure was linked to damage done by autoimmune attack to the capillaries that supply blood to the pancreas. To repair this damage they injected diabetic rats with either bone marrow cells or purified bone marrow progenitor cells in combination with Ig-GAD2.

The investigators reported that when the mice received bone marrow cells together with Ig-GAD2, in addition to immune modulation there was concomitant formation of new beta- and endothelial cells in the pancreas. The new beta cells were of host origin while the donor bone marrow cells gave rise to the endothelial cells. On the other hand, transfer of purified bone marrow endothelial progenitors instead of whole bone marrow cells sustained both beta- and endothelial cell formation and reversal of diabetes.

Related Links:
University of Missouri



view channel
Image: Schematic representation of HIV DART binding to two distinct antigens simultaneously, redirecting the killer T-cells to destroy HIV-1 infected cells (Photo courtesy of Duke University).

Bi-Specific Antibodies Shown to Clear Latent HIV Infections

Bi-specific antibodies or DARTS (dual-affinity re-targeting proteins) have been used to eliminate latent HIV-infection from patient samples by redirecting polyclonal T-cells to specifically engage with... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Sale of Mexican Pharmaceutical Company Expected to Boost Latin American Prescription Drug Market

The sale of a major Mexican pharmaceutical company to an international generic drug corporation is expected to accelerate the growth of the Latin American market for prescription drugs. Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel) announced that it has entered into definitive agreements to buy Representaciones... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.